Zacks.com featured highlights include OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham

For Immediate Release

Chicago, IL – January 30, 2025 – Stocks in this week’s article are OppFi Inc. OPFI, Corcept Therapeutics Inc. CORT, DXP Enterprises Inc. DXPE, Perpetua Resources Corp. PPTA and Graham Corp. GHM.

Buy These 5 Stocks with Recent Price Strength Amid a Volatile Early 2025

U.S. stock markets have been facing severe volatility since the beginning of 2025. Market participants are concerned about the forward trajectory of both inflation and interest rates. Moreover, treasury yields remain elevated.

Investors also remained concerned about the impact of the Trump administration's protectionist tariff policies. This week, the Chinese artificial intelligence startup DeepSeek's large language model R1 created a ruckus in the U.S. technology sector. Moreover, a strong U.S. economy, a resilient labor market and sticky inflation have raised concerns about the number of interest rate cuts this year.

Consequently, a handful of stocks have shown price strength. We have primarily targeted stocks that have recently been on a bull run. Such stocks have a high chance of carrying the momentum forward.

Five such stocks are — OppFi Inc., Corcept Therapeutics Inc., DXP Enterprises Inc., Perpetua Resources Corp. and Graham Corp..

If a stock is continuously witnessing an uptrend, there must be a solid reason or it would have probably crashed. So, looking at stocks capable of beating the benchmark that they have set for themselves seems rational.

However, recent price strength alone cannot create magic. Therefore, other relevant parameters are needed to create a successful investment strategy.

Here's how you should create the screen to shortlist the current as well as the potential winners.

Let's discuss these five stocks here:

OppFi Inc. is a tech-enabled specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. OPFI supports consumers, who are turned away by mainstream options, to build financial health, through transparency, responsible lending, financial inclusion, and a better customer experience.

The stock price of OppFi has soared 81.2% in the past four weeks. The company has expected earnings growth of 16.3% for the current year. The Zacks Consensus Estimate for the current year has improved 16.3% over the last 60 days.

Corcept Therapeutics Inc. is engaged in the discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. CORT offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, and for those who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

CORT is also developing relacorilant, which is in phase III clinical trial for the treatment of Cushing's syndrome, treatment for adrenal cancer and cortisol excess, which is in phase 1b clinical trial, treatment for prostate cancer which is in phase II clinical trial and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.

The stock price of Corcept Therapeutics has jumped 20.4% in the past four weeks. It has an expected earnings growth rate of 36.4% for the current year. The Zacks Consensus Estimate for current-year earnings improved 3.4% over the last 90 days.

DXP Enterprises Inc. is a leading products and service distributor that adds value and total cost savings solutions to industrial customers throughout the United States, Canada, Mexico and Dubai.

DXPE provides innovative pumping solutions, supply-chain services and maintenance, repair, operating and production services. DXPE's breadth of MROP products and service solutions allows it to be flexible and customer-driven, creating competitive advantages for our customers.

The stock price of DXP Enterprises has climbed 19.8% in the past four weeks. The company has expected earnings growth of 5.9% for the current year. The Zacks Consensus Estimate for the current year has improved 11.7% over the last 60 days.

Perpetua Resources Corp. is engaged in the exploration and development of mineral properties in the United States. PPTA primarily explores gold, silver, and antimony deposits.

PPTA is focused on the exploration, site restoration and redevelopment of gold-antimony-silver deposits principally in the Stibnite-Yellow Pine district of central Idaho which are encompassed by the Stibnite Gold Project.

The stock price of Perpetua Resources has advanced 6.7% in the past four weeks. It has an expected earnings growth rate of 25.4% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 20% over the last 60 days.

Graham Corp. designs and builds vacuum and heat-transfer equipment for process industries and energy markets worldwide. GHM's products include steam jet ejector vacuum systems and liquid ring vacuum pumps, surface condensers, Heliflows, water heaters, and various types of heat exchangers. GHM markets to chemical, petrochemical, petroleum refining, and electric power generating industries, including cogeneration and geothermal plants.

The stock price of Graham rose 0.5% in the past four weeks. The company has expected earnings growth of more than 100% for the current year (ending March 2025). The Zacks Consensus Estimate for the current year has improved 13.7% over the last 90 days.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/1878245/5-dividend-growth-stocks-for-safe-and-consistent-income

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.

Follow us on Twitter:  https://www.twitter.com/zacksresearch

Join us on Facebook:  https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto

Company: Zacks.com

Phone: 312-265-9268

Email: pr@zacks.com

Visit: https://www.zacks.com/

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research